

REMARKS

Preliminary Amendment


In the accompanying Preliminary Amendment, claim 13 is amended to clarify the full name of the abbreviation “AMPA.” Support for the amendment may be found by the disclosure of the specification, for example, on page 3, lines 10-15.

Claims 17 and 18 are newly added to further limit the subject matter of claim 13. Thus, claims 17 and 18 fall into Group IV. Support for new claims 17 and 18 may be found by the disclosure of the specification, for example, Table on page 11. The compound recited in claim 17 is the compound “GYKI 52466” and the compound recited in claim 18 is Talampanel, of which structure and full name are described in US 5,639,751 and RN 161832-65-1, as indicated in the Table. No matter has been introduced, and entry and consideration of the amendment is respectfully requested.

Response to Restriction Requirement

In response to the Restriction Requirement dated July 3, 2008, Applicants elects Group IV, claims 13-16 for examination without traverse.

In response to the Election of Species Requirement, Applicants elect the compound “7-acetyl-5-(4-aminophenyl)-8(R)-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine (Talampanel)”:



Response to Restriction and Election of Species Requirements and Amendment
Application No.: 10/509,379

This elected compound is recited in claim 18.

Claims 13 and 18 read on the elected species.

Applicants submit that if any of the elected claims is found to be allowable, claims dependent therefrom should similarly be considered allowable in the same application.

Applicants reserve the right to file a Divisional Application directed to non-elected claims 1-12.

Respectfully submitted,

/Sunhee Lee/

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Sunhee Lee
Registration No. 53,892

Date: August 1, 2008